Stem/Stromal Cells for Treatment of Kidney Injuries With Focus on Preclinical Models
Within the last years, the use of stem cells (embryonic, induced pluripotent stem cells, or hematopoietic stem cells), Progenitor cells (e.g., endothelial progenitor cells), and most intensely mesenchymal stromal cells (MSC) has emerged as a promising cell-based therapy for several diseases includin...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-06-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fmed.2018.00179/full |
id |
doaj-bf522080ae6f4ecaa19d04b2c696bac0 |
---|---|
record_format |
Article |
spelling |
doaj-bf522080ae6f4ecaa19d04b2c696bac02020-11-25T01:03:12ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2018-06-01510.3389/fmed.2018.00179374710Stem/Stromal Cells for Treatment of Kidney Injuries With Focus on Preclinical ModelsAdriana Torres Crigna0Cristina Daniele1Carolina Gamez2Sara Medina Balbuena3Diego O. Pastene4Daniela Nardozi5Cinzia Brenna6Benito Yard7Norbert Gretz8Karen Bieback9Medical Faculty Mannheim, Institute of Transfusion Medicine and Immunology, University of Heidelberg, German Red Cross Blood Service Baden-Württemberg-Hessen, Mannheim, GermanyMedical Faculty Mannheim, Medical Research Centre, University of Heidelberg, Mannheim, GermanyDepartment for Experimental Orthopaedics and Trauma Surgery, Medical Faculty Mannheim, Orthopaedic and Trauma Surgery Centre (OUZ), Heidelberg University, Mannheim, GermanyDepartment of Medicine (Nephrology/Endrocrinology/Rheumathology), University Medical Centre Mannheim, University of Heidelberg, Mannheim, GermanyDepartment of Medicine (Nephrology/Endrocrinology/Rheumathology), University Medical Centre Mannheim, University of Heidelberg, Mannheim, GermanyMedical Faculty Mannheim, Medical Research Centre, University of Heidelberg, Mannheim, GermanyMedical Faculty Mannheim, Medical Research Centre, University of Heidelberg, Mannheim, GermanyDepartment of Medicine (Nephrology/Endrocrinology/Rheumathology), University Medical Centre Mannheim, University of Heidelberg, Mannheim, GermanyMedical Faculty Mannheim, Medical Research Centre, University of Heidelberg, Mannheim, GermanyMedical Faculty Mannheim, Institute of Transfusion Medicine and Immunology, University of Heidelberg, German Red Cross Blood Service Baden-Württemberg-Hessen, Mannheim, GermanyWithin the last years, the use of stem cells (embryonic, induced pluripotent stem cells, or hematopoietic stem cells), Progenitor cells (e.g., endothelial progenitor cells), and most intensely mesenchymal stromal cells (MSC) has emerged as a promising cell-based therapy for several diseases including nephropathy. For patients with end-stage renal disease (ESRD), dialysis or finally organ transplantation are the only therapeutic modalities available. Since ESRD is associated with a high healthcare expenditure, MSC therapy represents an innovative approach. In a variety of preclinical and clinical studies, MSC have shown to exert renoprotective properties, mediated mainly by paracrine effects, immunomodulation, regulation of inflammation, secretion of several trophic factors, and possibly differentiation to renal precursors. However, studies are highly diverse; thus, knowledge is still limited regarding the exact mode of action, source of MSC in comparison to other stem cell types, administration route and dose, tracking of cells and documentation of therapeutic efficacy by new imaging techniques and tissue visualization. The aim of this review is to provide a summary of published studies of stem cell therapy in acute and chronic kidney injury, diabetic nephropathy, polycystic kidney disease, and kidney transplantation. Preclinical studies with allogeneic or xenogeneic cell therapy were first addressed, followed by a summary of clinical trials carried out with autologous or allogeneic hMSC. Studies were analyzed with respect to source of cell type, mechanism of action etc.https://www.frontiersin.org/article/10.3389/fmed.2018.00179/fullmesenchymal stromal cellsMSC therapyrenal injuryacute kidney injurychronic kidney injurydiabetic nephropathy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Adriana Torres Crigna Cristina Daniele Carolina Gamez Sara Medina Balbuena Diego O. Pastene Daniela Nardozi Cinzia Brenna Benito Yard Norbert Gretz Karen Bieback |
spellingShingle |
Adriana Torres Crigna Cristina Daniele Carolina Gamez Sara Medina Balbuena Diego O. Pastene Daniela Nardozi Cinzia Brenna Benito Yard Norbert Gretz Karen Bieback Stem/Stromal Cells for Treatment of Kidney Injuries With Focus on Preclinical Models Frontiers in Medicine mesenchymal stromal cells MSC therapy renal injury acute kidney injury chronic kidney injury diabetic nephropathy |
author_facet |
Adriana Torres Crigna Cristina Daniele Carolina Gamez Sara Medina Balbuena Diego O. Pastene Daniela Nardozi Cinzia Brenna Benito Yard Norbert Gretz Karen Bieback |
author_sort |
Adriana Torres Crigna |
title |
Stem/Stromal Cells for Treatment of Kidney Injuries With Focus on Preclinical Models |
title_short |
Stem/Stromal Cells for Treatment of Kidney Injuries With Focus on Preclinical Models |
title_full |
Stem/Stromal Cells for Treatment of Kidney Injuries With Focus on Preclinical Models |
title_fullStr |
Stem/Stromal Cells for Treatment of Kidney Injuries With Focus on Preclinical Models |
title_full_unstemmed |
Stem/Stromal Cells for Treatment of Kidney Injuries With Focus on Preclinical Models |
title_sort |
stem/stromal cells for treatment of kidney injuries with focus on preclinical models |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Medicine |
issn |
2296-858X |
publishDate |
2018-06-01 |
description |
Within the last years, the use of stem cells (embryonic, induced pluripotent stem cells, or hematopoietic stem cells), Progenitor cells (e.g., endothelial progenitor cells), and most intensely mesenchymal stromal cells (MSC) has emerged as a promising cell-based therapy for several diseases including nephropathy. For patients with end-stage renal disease (ESRD), dialysis or finally organ transplantation are the only therapeutic modalities available. Since ESRD is associated with a high healthcare expenditure, MSC therapy represents an innovative approach. In a variety of preclinical and clinical studies, MSC have shown to exert renoprotective properties, mediated mainly by paracrine effects, immunomodulation, regulation of inflammation, secretion of several trophic factors, and possibly differentiation to renal precursors. However, studies are highly diverse; thus, knowledge is still limited regarding the exact mode of action, source of MSC in comparison to other stem cell types, administration route and dose, tracking of cells and documentation of therapeutic efficacy by new imaging techniques and tissue visualization. The aim of this review is to provide a summary of published studies of stem cell therapy in acute and chronic kidney injury, diabetic nephropathy, polycystic kidney disease, and kidney transplantation. Preclinical studies with allogeneic or xenogeneic cell therapy were first addressed, followed by a summary of clinical trials carried out with autologous or allogeneic hMSC. Studies were analyzed with respect to source of cell type, mechanism of action etc. |
topic |
mesenchymal stromal cells MSC therapy renal injury acute kidney injury chronic kidney injury diabetic nephropathy |
url |
https://www.frontiersin.org/article/10.3389/fmed.2018.00179/full |
work_keys_str_mv |
AT adrianatorrescrigna stemstromalcellsfortreatmentofkidneyinjurieswithfocusonpreclinicalmodels AT cristinadaniele stemstromalcellsfortreatmentofkidneyinjurieswithfocusonpreclinicalmodels AT carolinagamez stemstromalcellsfortreatmentofkidneyinjurieswithfocusonpreclinicalmodels AT saramedinabalbuena stemstromalcellsfortreatmentofkidneyinjurieswithfocusonpreclinicalmodels AT diegoopastene stemstromalcellsfortreatmentofkidneyinjurieswithfocusonpreclinicalmodels AT danielanardozi stemstromalcellsfortreatmentofkidneyinjurieswithfocusonpreclinicalmodels AT cinziabrenna stemstromalcellsfortreatmentofkidneyinjurieswithfocusonpreclinicalmodels AT benitoyard stemstromalcellsfortreatmentofkidneyinjurieswithfocusonpreclinicalmodels AT norbertgretz stemstromalcellsfortreatmentofkidneyinjurieswithfocusonpreclinicalmodels AT karenbieback stemstromalcellsfortreatmentofkidneyinjurieswithfocusonpreclinicalmodels |
_version_ |
1725201764741808128 |